AI Biologics discovery & engineering services
Design, prioritize and optimize antibody and protein candidates with computational biology, structural modeling and program-specific AI support.
AI for biologics from candidate generation to lead optimization
As a Bio-ML engineering partner, Ardigen provides biologics discovery and engineering services for teams generating candidates, screening hits, or optimizing lead candidates. We combine structural biology, bioinformatics, physics-based modeling, and AI tailored to your modality and available data.
Key capabilities for biologics discovery & engineering
Accurate target characterization
Analyze target structure, biological context, epitopes and interaction regions to define the design and screening question.
Effective lead generation
Explore sequence and structural design spaces to generate and evaluate diverse candidates for experimental validation.
Intelligent hit screening
Compare candidates across binding, specificity and relevant biologics developability indicators, including stability, solubility, aggregation and immunogenicity risk.
Binder-target interaction profiling
Apply interface analysis, structure prediction and biophysical modeling to evaluate selectivity and potential off-target liabilities.
AI solutions grounded 
in biology for biologics discovery
With advanced AI models, state-of-the-art bioinformatics, and physics-based tools at your disposal, you can engineer biologics that are selective, precise, and developable -accelerating your discovery pipeline.
De novo lead generation
Generate candidate sequences or structures for a defined target, interaction site or scaffold, using methods tailored to the modality.
Hit screening
Prioritize existing or generated candidates against defined binding, specificity and developability criteria before selecting the next experimental set.
Lead optimization
Evaluate focused sequence changes, affinity-maturation options, and property trade-offs across potency, selectivity, stability, and downstream manufacturability.
Deep molecular insights
Ardigen combines AI-supported analysis with physics-based techniques, such as protein-protein docking and molecular dynamics where appropriate, to examine biologic structures and binder-target interactions.
Model complex biologic structures from sequence and available structural evidence.
Analyze conformational behavior, structural changes and molecular interactions.
Characterize residue-level interactions and interface binding modes to guide the design process.
Why teams use Ardigen for AI-driven biologics discovery
Advanced AI solutions for biologics discovery
Apply sequence, structure and generative methods tailored to the target, modality and decision criteria.
Comprehensive scientific context
Connect AI outputs with bioinformatics, structural biology and physics-based analysis rather than relying on a single method or score.
Structured project
delivery
Receive a defined work package with inputs, methods, assumptions, candidate-level rationale, and a seamless handoff for wet-lab validation.
Custom deployment & team enablement
Deploy our proven biologics discovery and engineering workflows directly into your secure cloud or internal HPC, with zero proprietary SaaS lock-in, transparent codebases, and full scientific and engineering support.
See the impact
AI in Biologics Case Studies
Frequently Asked Questions
How does AI accelerate biologics discovery and development?
AI can help teams analyze sequence, structure, binding and developability evidence across a larger candidate set. It supports candidate generation, screening and lead optimization while experimental testing confirms biological activity and development suitability. Ardigen can work alongside an internal team or biologics CRO with responsibilities defined in the project scope.
What does "AI for Biologics" include: antibodies, peptides, proteins?
AI for biologics can support antibodies and antibody-derived binders, peptides, miniproteins, recombinant proteins and other amino-acid-based modalities. The exact workflow depends on the format, available structural evidence and experimental plan.
How does AI enhance lead generation and hit screening for biologics?
Models can propose candidates and compare them using sequence, structural, predicted binding and developability evidence. The result should be a reviewable shortlist with clear criteria for the next laboratory cycle.
How can AI design de novo biologics?
Generative and structure-based methods can propose new sequences or structures against a defined interaction context. Candidate selection should also consider specificity, stability, solubility, aggregation, immunogenicity and manufacturability requirements relevant to the program.
What is the role of AI in predicting immunogenicity or stability of biologics?
Computational models can flag sequence or structural patterns associated with immunogenicity, instability, aggregation and other developability risks. These assessments guide prioritization and testing; they do not replace experimental characterization.
Contact
Discuss your biologics discovery program
Share your target, modality, candidate set, available data and next R&D milestone. Ardigen will evaluate your requirements and structure a tailored computational scope to advance your program.
Send us a message and we will contact you back within 48 hours.
Newsletter
Become an insider
Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!